Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus - PubMed (original) (raw)

Multicenter Study

. 2019 Nov 5;140(19):1569-1577.

doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.

Stephen D Wiviott 1, Benjamin M Scirica 1, Yared Gurmu 1, Ofri Mosenzon 2, Sabina A Murphy 1, Deepak L Bhatt 1, Lawrence A Leiter 3, Darren K McGuire 4, John P H Wilding 5, Per Johanson 6, Peter A Johansson 6, Anna Maria Langkilde 6, Itamar Raz 2, Eugene Braunwald 1, Marc S Sabatine 1

Affiliations

Multicenter Study

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

David D Berg et al. Circulation. 2019.

Abstract

Background: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing heart failure. Sodium-glucose cotransporter-2 inhibitors reduce the risk of hospitalization for heart failure (HHF) in patients with T2DM. We aimed to develop and validate a practical clinical risk score for HHF in patients with T2DM and assess whether this score can identify high-risk patients with T2DM who have the greatest reduction in risk for HHF with a sodium-glucose cotransporter-2 inhibitor.

Methods: We developed a clinical risk score for HHF in 8212 patients with T2DM in the placebo arm of SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53). Candidate variables were assessed using multivariable Cox regression, and independent clinical risk indicators achieving statistical significance of P<0.001 were included in the risk score. We externally validated the score in 8578 patients with T2DM in the placebo arm of DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58). The relative and absolute risk reductions in HHF with the sodium-glucose cotransporter-2 inhibitor dapagliflozin were assessed by baseline HHF risk.

Results: Five clinical variables were independent risk predictors of HHF: prior heart failure, history of atrial fibrillation, coronary artery disease, estimated glomerular filtration rate, and urine albumin-to-creatinine ratio. A simple integer-based score (0-7 points) using these predictors identified a >20-fold gradient of HHF risk (P for trend <0.001) in both the derivation and validation cohorts, with C indices of 0.81 and 0.78, respectively. Although relative risk reductions with dapagliflozin were similar for patients across the risk scores (25%-34%), absolute risk reductions were greater in those at higher baseline risk (1-sided P for trend=0.04), with high-risk (2 points) and very-high-risk (≥3 points) patients having 1.5% and 2.7% absolute reductions in Kaplan-Meier estimates of HHF risk at 4 years, respectively.

Conclusions: Risk stratification using a novel clinical risk score for HHF in patients with T2DM identifies patients at higher risk for HHF who derive greater absolute benefit from sodium-glucose cotransporter-2 inhibition.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01107886 and NCT01730534.

Keywords: diabetes mellitus; heart failure; risk factors; sodium-glucose cotransporter-2 inhibitors.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.. Incidence rate of hospitalization for heart failure by risk score in the derivation and validation cohorts.

The incidence rates of hospitalization for heart failure in the derivation and validation cohorts are shown. The integer-based scheme identified a >20-fold gradient of risk in both the derivation (χ2W 819.4; p-trend <0.001) and validation cohorts (χ2W 724.3; p-trend <0.001). HHF indicates hospitalization for heart failure.

Figure 2.

Figure 2.. Treatment effect of dapagliflozin by baseline risk of hospitalization for heart failure.

Whereas relative risk reductions were similar across risk score categories, absolute reductions in Kaplan-Meier estimates of hospitalization for heart failure (HHF) risk at 4 years (i.e., ARR) were greater in those at higher baseline risk (χ2 3.24; one-sided p-trend=0.04). ARR indicates absolute risk reduction; HR, hazard ratio; NNT, number needed to treat.

Similar articles

Cited by

References

    1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. - PubMed
    1. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, Committee S-TS and Investigators*. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588. - PubMed
    1. Cavender MA, Steg PG, Smith SC Jr., Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL and Investigators RR. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132:923–931. - PubMed
    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O’Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS, American Heart Association Council on E, Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56–e528. - PubMed
    1. Boudina S and Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources